Evidence map›Paper›PMID 35184383›Full record

ArticleProteomics2022

Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.

Michele Mishto, Yehor Horokhovskyi, John A Cormican, Xiaoping Yang, Steven Lynham, Henning Urlaub, Juliane Liepe

Open access · hybridAbstract read
In one paragraph

Article in Proteomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Michele MishtoCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, UK.ORCID 0000-0003-3042-2792
Yehor HorokhovskyiMax-Planck-Institute for Multidisciplinary Sciences, Göttingen, Germany.
John A CormicanMax-Planck-Institute for Multidisciplinary Sciences, Göttingen, Germany.
Xiaoping YangProteomics Core Facility, James Black Centre, King's College, London, UK.
Steven LynhamProteomics Core Facility, James Black Centre, King's College, London, UK.
Henning UrlaubMax-Planck-Institute for Multidisciplinary Sciences, Göttingen, Germany.
Juliane LiepeMax-Planck-Institute for Multidisciplinary Sciences, Göttingen, Germany.
King's College London · GBMax Planck Institute for Multidisciplinary SciencesUniversitätsmedizin Göttingen · DE

Funding

Cancer Research UK 29686Cancer Research UK A29686Cancer Research UK C67500Department of Health
6 · The paper itself

Abstract

Unconventional epitopes presented by HLA class I complexes are emerging targets for T cell targeted immunotherapies. Their identification by mass spectrometry (MS) required development of novel methods to cope with the large number of theoretical candidates. Methods to identify post-translationally spliced peptides led to a broad range of outcomes. We here investigated the impact of three common database search engines - that is, Mascot, Mascot+Percolator, and PEAKS DB - as final identification step, as well as the features of target database on the ability to correctly identify non-spliced and cis-spliced peptides. We used ground truth datasets measured by MS to benchmark methods' performance and extended the analysis to HLA class I immunopeptidomes. PEAKS DB showed better precision and recall of cis-spliced peptides and larger number of identified peptides in HLA class I immunopeptidomes than the other search engine strategies. The better performance of PEAKS DB appears to result from better discrimination between target and decoy hits and hence a more robust FDR estimation, and seems independent to peptide and spectrum features here investigated.

Indexed as

PeptidesSearch EngineEpitopesMass SpectrometrySoftwareEpitopesPeptidesHLAimmunopeptidomeMascotPEAKSpeptide splicing

Identifiers

PMID35184383
PMCPMC9286349
OpenAlexW4213072393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.